Post-transplant
Iymphoproliferative disorders (PTLD) comprise a range of lymphoid tumors divisible into several c\inicopa thological categories ( I). Most PTLDs are of B ceil origin and contain the Epstein· Barr virus (EB\'). which is considered to be a major cofac10r for their dewlopment (2. 3).
It has been estimated that between 3) and 50'~'" of all PTLDs may regress following reduction of iatrogenic immunosuppression (4. 5) . and this is consistent with the concept that host immunity plays a role in controlling the growth of such lesions (6). Examination of the microenvironment of PTLDs may. therefore. help to define a) the milieu within which tumor growth occurs: and bl intratumoral changes that occur during the process of tumor regression.
The present study analyzes PTLDs for expression of mRNAs encoding several cytokines that may directly or indirectly influence B lymphocyte growth. In addition. semiquantitative and longitudinal evaluations of cytokine mR NAs from bronchoalveolar lavage (BAL) specimens in patients with lung-based PTLDs were performed to detect changes following resolution of these tumors.
Materials and methods

Specimens
Twelve tissue specimens from 7 patients with PTLD were obtained as byproducts of diagnostic or therapeutic procedures performed at the University of Pittsburgh Medical Center. Pittsburgh.
:\alesnik et al.
PA from May 1990 to February 199:2. Tissues were obtained with approval of the Institutional Review Board. Eleven of these specimens represented PTLD tumors and the twelfth specimen derived from a splenectomy performed on a patient with PTLD at a separate site.
Two spleen specimens from transplant patients without evidence of PTLD were used as control tissues. Six reactive lymph nodes and one splenic specimen from nontransplant patients were also used as technical controls.
Tissues were snap-frozen in liquid nitrogencooled isopentane and stored at -80°C until use.
Fresh cells were obtained as byproducts of BAL in two additional patients with pulmonary PTLO. both at the times of tumor diagnosis and following tumor resolution. The clinical course of one of these patients has been reported previously (7) . BALs were performed in a third lung transplant recipient without evidence of PTLO both at the time of allograft rejection and following resolution of rejection.
Cytokine mRNA polymerase chain reaction Total RNA was extracted from frozen tissues or cells and eDNA synthesis was carried out as previously described (7). Polymerase chain reaction (PCR) primers for IL2. IL4. IL6. ILIO and IFNI were synthesized at the l.J niversity of Pittsburgh DNA facility. Commercial primers for EBY (Research Genetics. Huntsville. AL) were also utilized. and primers detecting actin were used as positive controls for each specimen. Qualitative PCR using cDNA from solid tissue samples was carried out for 30 cycles and the products visualized with ethidium bromide.
BAL cell cDNA samples were analyzed for the expression of cytokine mRNA using a semi-quantitati\:e reverse transcriptase-PCR (RT-PCR) with 1 1 P-deoxycytidine triphosphate-labelled oligoprimers. quantitated on a Betagen radioanalytic scanner and the results were expressed as counts per min. ~-actin mRNA was measured as an internal control for each BAL specimen. The results are reported as the ratio of cytokine per actin mR~.-\.
Results
Clinicopathologic features of post-transplant Iymphoproliferative disordersg
Clinicopathologic features of the study specimens are shown in Table I . Solid tissue samples were obtained from patients 1-7. and patients 8-10 were the sources of BAL specimens. Two or more PTLOs were sampled in 3 patients. In one case (patient II. a pharyngeal lesion arose 5 months following resection of a PTLD that was connned to the allograft liver. Both tumors had the appear- 
. ance of a large cell non-Hodgkin's lymphoma (monomorphic PTLD) and both demonstrated identical rearrangements of the immunoglobulin heavy chain gene. In patients 2 and 3. synchronous and noncontiguous tumors were sampled. In one case (patient 2). the presence of two separate clonal proliferations was documented. PTLD was not further categorized in patients 8 and 9. both of whom had pulmonary lesions.
Treatment included reduction of immunosuppression and acyclovir in all cases. Patient 3 required allograft resection and patient 7 received subsequent chemotherapy. Patient 9 received additional therapy with '.X-interferon.
PTLD resoh'ed in 5 patients (Nos. I. 4. 7-9) and the remaining 4 tumor patients (Nos. 2. 3. 5. 6) expired with PTLD. Patient 10. included as a control. did not have PTLD at any lime during the post-transpbnt course.
EBV status of PTLOs
All II solid tissue PTLD specimens were positive for EBV by peR analysis (Table 2 ). Specimen 6. taken from uninvolved spleen in a PTLD patient. was negative for this target. A pulmonary biopsy from patient 9 was positive for EBV by in situ hybridization for Epstein -Barr early RNA (EBER). Insufficient tissue was available from patient 8 to perform this assay.
Cytoklne mRNA profiles of PTLOs All 12 specimens from PTLD patients showed a similar qualitative cytokine mRNA profile of IL:! ~ . IFNy -. I L4 -. III 0 + (Table 2) . Representative patterns of two separate tumors resected 5 months apart from patient I are shown in Fig. 1 . In this example. the first tumor represented a PTLD c~·tokines lymphomatous PTLD. which was localized to the allograft. The second tumor arose in the pharynx after a 5-month tumor-free inten·al. Pathologic evaluation of this case was previously reported and it was concluded that the second lesion represented a true recurrence of the primary tumor (8).
In patient 6. splenectomy was performed at the time of acti\c PTLD. Although the spleen itself was not in\olved by tumor. it demonstrated a cytokine mRNA pratlle similar to that seen in PTLD specimens. I.!xcept for the absence of EBV.
Two splenic specimens were obtained from transplant recipients at the time of acute rejection. Both specimens were negative for EBV. In one case the cytokine mRNA pattern was IL:! -. IFNy·. IL4+. ILlO-and in the other it was IU4-. IFNy~. IL4-. ILIO-. A splenic specimen obtained from 1 non transplant patient was associated with a pattern similar to that found in the PTLDs. except for the absence of EBV. Six lymph nodes from 5 nontransplant patients were also analyzed. All were EBV negative. In one case no cytokine mRNA was detected. in two cases only weak expression of ILl 0 mR N A was seen. and in one case ILIO positivity was coupled with weak expression (A) ...i - BAL cells from the 2 lung transplant recipients with biopsy-proven pulmonary PTLD revealed strong expression of IL4 mRNA when analyzed by semiquantitative RT-PCR (Table 3) . Prominent ILID mRNA expression was also seen in one case (specimen 9A. Table -,) and was expressed to a lesser extent in the second case. In contrast to the results of qualitative analysis, some expression of IL2 and IFNy mRNA was observed in both of these patients. IL6 mRNA was also detected in both specimens.
Decreased levels of all of the above cytokine mRNAs relative to actin mRNA were seen in BAL specimens taken from both of these patients at time of PTLD resolution.
In contrast to this pattern, IL6 and IFN'( were the predominant cytokine mRNAs found during an acnte rejection episode in patient 10 (specimen lOA. Table 3 ). Relative val ues for these cytokines also decreased following successful treatment of rejection.
No correlation between the original PTLD cytokine profile and histology, c!onality, time interval from transplant to tumor. tumor location or response to treatment could be inferred from this study.
Discussion
The results of this study suggest that many PTLDs exist within a T-helper cell type 2 (Th2)-1ike (9) cytokine environment. In all PTLD specimens analyzed by qualitative RT-PCR in this series, IL4 and ILIO mRNA were present and neither IL2 nor IFNi were found. This pattern was not seen in either of two splenic specimens obtained from transplant patients v.ithout PTLD, nor in any of six control lymph nodes resected from nontransplant patients. The sole exception occurred in a spleen resected from I nontransplant patient. Use of a more sensitive semiquantitative technique again showed predominance of IL4 or IL4 to- (12) who were the first to describe a decrease in blood levels of :t-interferon and an increase in circulating IL4 levels in a cohort of bone marrow transplant patients with PTlD. Immunosuppressed transplant recipients without PTLD also had elevated IL.+ levels relative to a nontransplant popUlation, but did not demonstrate a depression of :x-interferon as did the PTlD patients. Similarly. Burke et al. (13) demonstrated decreased serum IL2 in conjunction with a rise in serum IL4 in a patient with disseminated PTLD. The presence of a systemic Th2-like cytokine profile during PTLD is also suggested by the specimen from patient 6 in the current study. In this case. the patient had a PTLD that did not invohe the spleen. Nevertheless. a Th2-like cytokine mRNA profile was identified in the test sample derived from this organ. This may be coincidental. or it may ret'Iect a systemic Th2-like pattern during PTLD as suggested by others (12. 131.
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The role of individual cytokines within PTLD remains speculative. For example. IL-+ may selectively drive T cells toward a Th2 phenotype. in addition to having a stimulatory effect on B cells (14) . It seems likely that either or both of these activities may contribute to PTLD development. but this has not yet been formally proven.
ILiD is also known to suppress the Th I cytokine response (14) . and the absence of detectable Thlassociated cytokines IL2 or IFN'! in the solid PTLD specimens is consistent with this role. Howe\er. ILIO may also be demonstrated locally in the context of acute cellular rejection. which is not associated with a Th2-predominant pattern (15. 161. Th us. the demonstra tion of this cytokine alone does not predict the overall cytokine milieu.
ILIO may also sen'e as an autocrine paracrine gr\.)\\ th factor for B-Iymphocytes. and one study showed this c1Tect using spontaneous Iymphoblastoid B cell lines deri\ed from the blood of a patient with PTLD (17L Ho\\ewr. Randha\\a et al. (18) failed to show growth stimulation l,f a PTLDderi\cd B cell line upon addition of recombinant ILIO. despite the fact that the cell line itself prodw.:cd ILIO. Similarly. ILIO-stimulated B cell grll\\lh could not be demonstrated by Kanno et al. ([9) in a separate study of a pyothorax-associated EBY-positi\'e B cell lymphoma from a nonimmunosuppressed patient.
Re\'ersal of the Th2 pattern coincident with PTLD resolution in 2 patients \\ith longitudinal sample analysis lends support to efforts designed to bring about a host antitumor response by use of immuIlllmodulatil1n. like the withdrawal of imm Utwsupprcssion \Jr administration of Th I-associated cytokines (20) . such as :x-interferon (il. It is also concei\abk that the use of anti-cytokine antibodies such as anti-IL4 and possibly anti-IL-IO antibodies ma~ alter the PTLD microenvironment and thus facilitate a cytotoxic host antitumor response. Such approaches could concei\ably be combined with newer methods of adopti\e cellular immunotherapy (.~1-23) in order to generate an enhanced anti-tumor response with a reduced risk of organ rejection. Toward this end. further description of PTL D-associated cytokines and an anal~ sis of the function of these cytokines within these tumors appear warranted.
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